Trulieve and Curaleaf Compete for Market Dominance in Q2 Retail Expansion
By Sheeba M. | April 30, 2026 Trulieve and Curaleaf Compete for Market Dominance in Q2 Retail Expansion TL;DR: Major retailers expand store counts while maintaining profitability—institutional investors watch for margin pressure and consolidation opportunities ahead. The cannabis retail landscape is heating up as Trulieve Cannabis and Curaleaf Holdings compete aggressively for market share across […]
Global Cannabis Expansion: Mexico, Germany, and Australia Racing for Market Share
By Sheeba M. | April 30, 2026 Global Cannabis Expansion: Mexico, Germany, and Australia Racing for Market Share TL;DR: Mexico legalized recreational cannabis. Germany is fast-tracking distribution. Australia just approved medical imports. U.S. MSOs with international footprints—especially GTBIF—are positioned for 3x revenue growth by 2028. If you’re tracking cannabis stocks and only looking at U.S. […]
Federal Rescheduling Timeline: What Schedule III Means for Investors
By Sheeba M. | April 30, 2026 Federal Rescheduling Timeline: What Schedule III Means for Investors TL;DR: If cannabis moves to Schedule III in H2 2026, institutional capital unlocks instantly. Banks enter, valuations spike 35-50%, and MSOs like CURLF recapture $12B in trapped equity value. The betting markets are shifting. Congressional momentum on cannabis rescheduling […]
CBD Market Expansion: Why 2026 Is Different From Previous Hype Cycles
By Sheeba M. | April 29, 2026 CBD Market Expansion: Why 2026 Is Different From Previous Hype Cycles TL;DR: FDA guidance on CBD products (issued Q1 2026) is clearing regulatory fog. CPG brands entering the space with legitimacy signal real market traction—not hype. CBD revenues could triple by 2028 from today’s $4.8B base. Remember the […]
Cannabis Retail Sales Surge: Q1 2026 Recovery Signals Market Stabilization
By Sheeba M. | April 29, 2026 Cannabis Retail Sales Surge: Q1 2026 Recovery Signals Market Stabilization TL;DR: Q1 2026 retail cannabis sales reached $6.2B, marking the first sustained recovery since mid-2024. Multi-state operators with strong MSO portfolios are poised for accelerated growth as consumer demand normalizes. After two years of margin compression and consolidation, […]
Q2 Cannabis Earnings: 5 Plays to Watch Before May 30
By Sheeba M. | April 29, 2026 Q2 Cannabis Earnings: 5 Plays to Watch Before May 30 TL;DR: CURLF, TLRY, and CRON report earnings in the next 30 days—watch for margin compression and guidance cuts as recreational demand normalizes post-legalization euphoria. Cannabis operator earnings are no longer binary bets. The sector has matured. May’s earnings […]
Cannabis ETFs vs Individual Stocks: Which Strategy Wins?
By Sheeba M. | April 29, 2026 Cannabis ETFs vs Individual Stocks: Which Strategy Wins? TL;DR: As cannabis legalization spreads, institutional investors are choosing diversified ETFs over individual picks—but savvy traders can still profit from emerging plays like CURLF and TLRY. The cannabis investment landscape has shifted dramatically. While 2020-2021 saw individual stock darlings like […]
Cannabis Banking Thaw: Regional Banks Eye Compliance-First Partnerships
By Sheeba M. | April 29, 2026 Cannabis Banking Thaw: Regional Banks Eye Compliance-First Partnerships TL;DR: Mid-size regional banks are quietly piloting cannabis banking solutions with compliance-first frameworks. This signals major institutional capital is preparing for a post-rescheduling landscape—bullish for public companies like CURLF and VERANO. The cannabis industry’s banking crisis—a chronic constraint since 2014—is […]
Cannabis MSOs Report Q1 2026 Margins Stronger Than Expected
By Sheeba M. | April 29, 2026 Cannabis MSOs Report Q1 2026 Margins Stronger Than Expected TL;DR: Major Multi-State Operators showing improved gross margins in Q1 2026 as supply normalization and pricing pressures ease. Watch CURLF, TRSSF, and CRLBF for positive guidance revisions. The cannabis Multi-State Operator (MSO) sector is showing signs of financial stabilization […]
Cannabis M&A War: Which Operator Becomes the Consolidator?
By Sheeba M. | April 28, 2026 Cannabis M&A War: Which Operator Becomes the Consolidator? TL;DR: Rescheduling valuation boom unlocks M&A math that was broken for three years. CURA leads recovery, GTBIF builds war chest, and TRUL eyes consolidation targets. First deal likely Q3 2026. For three years, cannabis M&A was frozen. Valuations were too […]